학술논문
Edoxaban treatment in atrial fibrillation in routine clinical care: One‐year outcomes of the prospective observational ETNA‐AF study in South Korean patients
Document Type
article
Author
Source
Journal of Arrhythmia, Vol 39, Iss 4, Pp 546-555 (2023)
Subject
Language
English
ISSN
1883-2148
1880-4276
1880-4276
Abstract
Abstract Background The real‐world outcomes of edoxaban treatment in patients with atrial fibrillation (AF) were analyzed in the ETNA‐AF (Edoxaban Treatment in Routine Clinical Practice) study involving data from multiple regional registries. This report addresses effectiveness and safety of edoxaban in the Korean ETNA‐AF population. Methods One‐year data from 1887 Korean ETNA‐AF participants were analyzed according to edoxaban dose and patient age and compared with results of other ETNA‐AF registries. Results Approximately 70% of patients received the recommended doses of edoxaban (60 mg/30 mg); non‐recommended 60 mg and 30 mg doses were prescribed to 9.6% and 19.8% of the patients, respectively. The proportions of reference age (